2019 coronavirus disease
Conditions
Interventions
Intervention group:Oral antiviral peptide LL-37 probiotic capsules
Control group:Oral Nimatralvir/Ritonavir tablets
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years; 2. The nucleic acid test result of COVID-19 is positive; 3. Patients who are clinically assessed as medium-sized COVID-19 (the diagnostic criteria refers to the Diagnosis and Treatment Plan for Pneumonia Infected by novel coronavirus (Tenth Edition for Trial Implementation).
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and renal insufficiency, drug allergy and other drug use contraindications; 2. Patients who are highly likely to progress to severe/critical disease according to clinical evaluation; 3. Participants who received SARS-CoV-2 monoclonal antibody treatment or prevention, or other antiviral treatment (including research treatment); 4. Participants who have previous/concurrent clinical research experience (have participated in research intervention in the past 30 days); 5. Female patients who are pregnant, nursing or preparing for pregnancy during the study period or male patients whose partners are preparing for pregnancy during the study period.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptom improvement rate of patients enrolled on the 28th day after the first administration;Viral load change;Incidence rate of adverse events/serious adverse events;Severity conversion rate;Death rate; | — |
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom improvement rate of patients enrolled on the 14th day after the first administration; | — |
Countries
China
Contacts
Public ContactGang Sun
Chinese PLA General Hospital
Outcome results
None listed